Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company's revenue for H1 2025 was 964 million yuan, a year-on-year decline of 4.8%, with a net profit attributable to shareholders of 47 million yuan, down 72.4%. However, Q2 2025 showed signs of recovery with revenue of 534 million yuan, a slight increase of 0.2% year-on-year, and a net profit of 39 million yuan, down 44.7%. The report suggests that with the gradual recovery of domestic medical equipment bidding in 2025, the company is expected to achieve revenue growth for the full year [1] - The ultrasound segment is anticipated to recover in 2025 due to the resumption of domestic bidding, new product launches, and breakthroughs in the overseas mid-to-high-end market. H1 2025 revenue for the ultrasound segment was 550 million yuan, down 9.9% year-on-year. The introduction of high-end products and the expansion of market demand are expected to drive growth [2] - The digestive endoscopy segment is also expected to see revenue growth driven by domestic bidding recovery and accelerated domestic substitution. H1 2025 revenue for this segment was 388 million yuan, a slight increase of 0.08% year-on-year. The company has made significant advancements in product capabilities and is expanding its high-end channels [3] - The non-ultrasound and endoscopy segment saw a significant increase in revenue, up 76.5% year-on-year in H1 2025, driven by the commercialization of new surgical and vascular intervention products. The company has launched several new products that are expected to contribute to long-term revenue growth [4] - The company's net profit margin is expected to improve, with a projected net profit margin of 4.88% for H1 2025, down 12 percentage points year-on-year. The report anticipates a recovery in net profit margin in H2 2025 due to the resumption of bidding and new product launches [5] Financial Summary - The company forecasts revenues of 2.318 billion yuan, 2.762 billion yuan, and 3.286 billion yuan for 2025, 2026, and 2027 respectively, representing year-on-year growth rates of 15.12%, 19.14%, and 18.97%. The net profit attributable to shareholders is expected to be 201 million yuan, 303 million yuan, and 415 million yuan for the same years, with corresponding growth rates of 41.34%, 50.52%, and 37.08% [10]